Develops a point-of-care diagnostic system that uses multiplexed dynamic predictive algorithms and lateral flow immunoassays to analyze lymph node biomarkers during lung cancer biopsies. This technology reduces the incidence of insufficient biopsy samples, enabling real-time decision-making and faster initiation of treatment, thereby improving patient outcomes and reducing healthcare costs.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Lung cancer biopsies frequently yield insufficient samples, requiring repeat procedures and delaying diagnosis and treatment. This leads to increased costs, patient anxiety, and delays in initiating critical therapies.
Solution
ROSE Diagnostics is developing a rapid point-of-care diagnostic system to improve the success rate of lung cancer biopsies. Their technology uses a panel of known lymph node biomarkers in a multiplexed lateral flow immunoassay format. The system enables real-time analysis of biopsy samples during the procedure, allowing clinicians to determine if sufficient tissue has been collected for accurate analysis. The disposable test cartridges are read on a small, portable reader, providing results within 5 minutes. By reducing the incidence of insufficient samples, ROSE Diagnostics aims to accelerate diagnosis, reduce healthcare costs, and improve patient outcomes.
Target Audience
The primary target audience includes pulmonologists, oncologists, and pathology labs involved in lung cancer diagnosis and treatment.
Features
- Multiplexed lateral flow immunoassay for rapid detection of lymph node biomarkers
- Point-of-care testing during biopsy procedures
- Portable reader for on-site analysis
- 5-minute test turnaround time
- Designed to reduce the need for repeat biopsies